A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)

Launched by OLIVIA NEWTON-JOHN CANCER RESEARCH INSTITUTE · Dec 20, 2021

Keywords

ClinConnect Summary

The I-FIRST Study is a clinical trial investigating a new treatment approach for patients with a type of thyroid cancer that has become resistant to traditional radioiodine therapy. This trial is specifically looking at patients who have mutations in the NRAS or BRAFV600E genes and are experiencing advanced or metastatic thyroid cancer. Participants in the trial will receive a combination of two medications, Trametinib and Dabrafenib, for 30 days. The goal is to see if these treatments can help restore the cancer's sensitivity to radioiodine, which is a common treatment for thyroid cancer.

To be eligible for the trial, participants must be at least 18 years old, have a confirmed diagnosis of thyroid cancer, and have shown evidence of cancer progression in the last year. They should also have specific genetic mutations and meet certain health criteria. Throughout the study, doctors will monitor how well the treatment works using special imaging techniques. This trial is currently recruiting participants, and it offers a potential new option for those who have limited treatment choices. If you or a loved one are considering participation, it's important to discuss this with your healthcare team to understand how this trial might fit into your treatment plan.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Histologically-confirmed differentiated (including poorly differentiated) thyroid cancer that is either locally advanced or metastatic.
• • 2. Age \> 18 years.
• • 3. Life expectancy \> 12 weeks.
• • 4. Documented radiological progression by RECIST 1.1 in last 12 months.
• 5. Radioiodine refractory (at least one of):
• • 1. one measurable lesion without radioiodine uptake on 131I scan,
• • 2. at least one measurable lesion that had progressed by RECIST criteria within 12 months of 131I therapy despite 131I avidity at time of treatment, or
• • 3. cumulative treatment with \>24 GBq (600 mCi) of 131I.
• • 6. At least one evaluable lesion as per RECIST v1.1 that has not been treated with local radiation therapy within 3 months prior to the first dose of TKI. Irradiated lesions can only be included as an evaluable lesion if it has shown radiological progression as per RECIST v1.1 on subsequent imaging following irradiation.
• • 7. NRAS or BRAF V600E mutation tested by NGS in a NATA accredited laboratory or by recognised sequencing platform.
• • 8. ECOG 0-1.
• • 9. Informed consent.
• 10. Adequate haematological and biochemical parameters:
• • 1. Haemoglobin ≥ 9g/dL
• • 2. Neutrophils ≥ 1.5 x 109/L
• • 3. Platelets ≥ 100 x 109/L
• • 4. INR ≤ 1.4
• • 5. Serum Creatinine ≤ 1.3 x ULN
• • 6. Estimated Creatinine Clearance ≥ 30 ml/min (by Cockcroft Gault Formula)
• • 7. Serum ALT and AST ≤ 2.5 x ULN
• • 8. Serum Total Bilirubin ≤ 1.5 x ULN.
• • 9. TSH suppression \<0.1mU/L or otherwise consistent with 2015 ATA Guidelines on Thyroid Cancer
• Exclusion Criteria:
• • 1. Anaplastic thyroid cancer.
• • 2. Suitable for curative surgery or radiotherapy.
• • 3. Other anti-cancer (including TKI) therapy in prior 6 weeks.
• • 4. Concurrent malignancy other than non-melanoma skin cancer. Prior malignancies treated with curative intent and no evidence of recurrence in past three years may be allowed upon discussion with the medical monitor.
• • 5. Unstable brain metastasis. Treated or non-treated brain metastasis are allowed if neurologically stable, asymptomatic, on a stable steroid dose for a period of 2 weeks, and not anticipated to require any intervention during the trial treatment period. If treated with radiation or surgery, any related AE's should have recovered to ≤ grade 1 prior to enrolment on trial.
• • 6. Pregnancy, breastfeeding or unwilling to use contraception in those of child-bearing age.
• • 7. Significant medical condition that would prevent compliance with study procedures.
• • 8. History of retinal vein occlusion or retinopathy.
• • 9. Iodine-containing contrast scan within 8 weeks of planned 124I scan.